This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Print Page  |  Contact Us  |  Report Abuse  |  Sign In  |  Register
News & Press: General News

Akcea announce positive topline results from a Phase 2 clinical study of AKCEA-APO(a)-LRx

Monday, September 24, 2018   (8 Comments)
Posted by: Sandra Tremulis
Share |

Akcea and Ionis Report Positive Data from Phase 2 Study of AKCEA-APO(a)-LRx

Study demonstrates significant Lp(a) reduction, favorable safety and tolerability profile

Ionis Pharmaceuticals, Inc.

Largest and longest study of Ionis’ LICA technology

Data to be presented as a late-breaking clinical trial presentation at AHA on November 10 in Chicago

CAMBRIDGE, Mass. and CARLSBAD, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) --  Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced positive topline results from a Phase 2 clinical study of AKCEA-APO(a)-LRx in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a), or Lp(a).  Additional data from the Phase 2 study will be presented as a late-breaking clinical trial presentation at the American Heart Association Scientific Sessions in Chicago November 10-12, 2018.

The goal of the Phase 2 study was to characterize the safety and tolerability of AKCEA-APO(a)-LRx and to inform dose and dose frequency selection for the planned Phase 3 cardiovascular outcomes study.  The randomized, double-blind, placebo-controlled, dose-ranging study included 286 patients with established CVD and high Lp(a) (baseline mean of approximately 100 mg/dL [250 nmol/L] – more than three times the upper limit of normal). All patients were treated for at least six months, with some patients treated up to one year. Results from the study show:

  • Statistically significant dose-dependent reductions of Lp(a) compared to placebo at all dose levels, including low monthly doses of AKCEA-APO(a)-LRx.
  • Most patients in the active group achieved Lp(a) reductions below the established threshold of risk for CVD events.
  • Treatment emergent adverse events were balanced between the active and placebo groups.
  • Most common adverse event was injection site reactions (ISRs). ISRs were mostly mild and occurred in a minority of patients.
  • No patient in the study experienced a confirmed platelet level below 100,000/mm3. The incidence of platelet levels below normal (140,000/mm3) was comparable between the active (10.5%) and placebo (14.9%) groups.
  • Approximately 90% of patients completed treatment and the rate of treatment discontinuation was comparable between the active and placebo groups.

“These data represent an important step forward for patients who have significant risk of premature death from cardiovascular disease due to their high levels of Lp(a). In this large Phase 2 study AKCEA-APO(a)-LRx, robustly lowered Lp(a) with a favorable safety and tolerability profile. In addition, the data from this study support the potential to treat patients with convenient, low volume monthly doses,” said Paula Soteropoulos, chief executive officer of Akcea Therapeutics. “These results are also encouraging as we continue to develop our LICA pipeline.” 

Elevated Lp(a) is an independent, hereditary risk factor for CVD that cannot be well-controlled with lifestyle modifications, such as diet or exercise, or with treatment using existing cholesterol-lowering therapies. It is estimated that there are 8 to 10 million people living with established cardiovascular disease driven by elevated levels of Lp(a). The Phase 2 clinical study of AKCEA-APO(a)-LRx is the largest study conducted specifically for patients with elevated Lp(a).

“After my personal experience at age 39 with severe Lp(a)-induced heart disease and nearly having a heart attack myself, I have met many others living with this silent killer that is under-recognized in the wider population,” said Sandra Revill Tremulis, founder of the Lipoprotein(a) Foundation. “Even after diagnosis, with no treatment the increased risk of heart disease and heart attack remains a serious burden. This is an important advancement in the identification of a potential novel medicine for patients with Lp(a)-driven cardiovascular disease.” ...more here


Shirley Mussmann says...
Posted Monday, May 13, 2019
I live in South Africa. Am I eligible to participate in the Phase 3 trials?
Jim McKenzie says...
Posted Wednesday, March 20, 2019
At 76 i find that i continue to have cold feet at night. My LP(a) is 140. Now eating 95% vegitarian diet, little if any alcohol, and lost 20 lbs with diet since Jan 2018. Looki g forward to more info on Phase 111 trials. Certainly I would participate.
Sandra Tremulis says...
Posted Friday, March 15, 2019
If you register with us here we will inform you when we have information on the Phase III trial
Rick White says...
Posted Friday, March 15, 2019
I would also be a interested in finding out how to participate in the phase 3 trials.
Jason Mongue says...
Posted Thursday, March 7, 2019
+1 to "how do you become a candidate for the trials?"
Devin Goodman says...
Posted Monday, February 11, 2019
@Don, I was in Phase 2. They haven't started recruiting for Phase 3 yet, it's still a ways out. Hopefully it will happen in 2019.
Administration says...
Posted Friday, February 1, 2019
Hi Don, if you register with us on this site we try to keep everyone informed of any news on trials etc. Sandra - Founder
Don Furtado says...
Posted Friday, February 1, 2019
How do you find out when the Phase 3 trials will take place and how do you become a candidate for the trials?

Community Search
Sign In
Login with LinkedIn

Latest News
809 Laurel Street #460
San Carlos, CA 94070